The Lycera team possesses extensive experience in the validation of new targets and the discovery of novel chemical matter. By employing diverse approaches to hit discovery, the Lycera team has a track record of identifying rapidly progressable drug-like compounds and advancing them through lead optimization to clinical candidate identification. Internal efforts are focused on a group of exciting immuno-oncology targets that represent high potential opportunities for the development of new cancer treatment paradigms.